Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Congenital adrenal hyperplasia

S Pang1

  • 1Department of Pediatrics, University of Illinois, Chicago, USA.

Endocrinology and Metabolism Clinics of North America
|January 16, 1998
PubMed
Summary
This summary is machine-generated.

Congenital adrenal hyperplasia (CAH) is a genetic disorder impacting cortisol production. Advances in genetics and biochemistry improve diagnosis and monitoring, but optimal growth and weight management therapies for CAH require further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Risk factors and chemoprophylaxis of ulcerative colitis-colorectal cancer].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2022
Same author

[Predicting value on short-term outcome of various established risk prediction models in extracorporeal membrane oxygenation treated cardiogenic shock patients due to ST-segment elevation myocardial infarction].

Zhonghua xin xue guan bing za zhi·2022
Same author

[Early effect of extracorporeal membrane oxygenation and factors related to early outcome in adult patients with fulminant myocarditis].

Zhonghua xin xue guan bing za zhi·2022
Same author

The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2022
Same author

Long noncoding RNA OIP5-AS1 exhibits oncogenic activity in bladder cancer through miR-217 and MTDH.

European review for medical and pharmacological sciences·2021
Same author

Evaluation of the Haemophilus influenzae EUCAST and CLSI disc diffusion methods to recognize aminopenicillin and amoxicillin/clavulanate resistance.

The Journal of antimicrobial chemotherapy·2020

Area of Science:

  • Endocrinology
  • Genetics
  • Pediatrics

Background:

  • Congenital adrenal hyperplasia (CAH) encompasses genetic disorders affecting cortisol biosynthesis due to mutations in adrenal steroidogenic enzyme genes.
  • Phenotypic variability in CAH is increasingly understood through molecular advances, enabling precise genotyping and prenatal diagnosis.
  • Biochemical advancements support CAH diagnosis and therapeutic monitoring.

Purpose of the Study:

  • To review recent molecular and biochemical advances in understanding and managing congenital adrenal hyperplasia (CAH).
  • To discuss the implications of these advances for diagnosis, family genotyping, prenatal prediction, and therapeutic monitoring.
  • To evaluate current treatment outcomes and identify areas for future therapeutic development in CAH.

Main Methods:

Related Experiment Videos

  • Review of recent molecular and biochemical research in congenital adrenal hyperplasia (CAH).
  • Analysis of genetic genotyping techniques for family members and prenatal diagnosis.
  • Evaluation of diagnostic and therapeutic monitoring strategies, including prenatal dexamethasone therapy and newborn screening.

Main Results:

  • Molecular advances clarify the genetic basis of CAH, enabling accurate genotyping and prenatal prediction.
  • Prenatal dexamethasone therapy can mitigate virilization in affected females but carries maternal side effects.
  • Newborn screening for CAH reduces morbidity from delayed diagnosis, benefiting over two-thirds of neonates.

Conclusions:

  • Genetic and biochemical progress has significantly improved CAH diagnosis and management.
  • Current CAH treatments may not ensure optimal growth and weight, necessitating exploration of novel therapeutic approaches.
  • Further research is essential to refine CAH therapies for improved long-term patient outcomes.